Literature DB >> 18956862

Fragment-based design of small molecule X-linked inhibitor of apoptosis protein inhibitors.

Jui-Wen Huang1, Ziming Zhang, Bainan Wu, Jason F Cellitti, Xiyun Zhang, Russell Dahl, Chung-Wai Shiau, Kate Welsh, Aras Emdadi, John L Stebbins, John C Reed, Maurizio Pellecchia.   

Abstract

We report on a general structure- and NMR-based approach to derive druglike small molecule inhibitors of protein-protein interactions in a rapid and efficient manner. We demonstrate the utility of the approach by deriving novel and effective SMAC mimetics targeting the antiapoptotic protein X-linked inhibitor of apoptosis protein (XIAP). The XIAP baculovirus IAP repeat 3 (Bir3) domain binds directly to the N-terminal of caspase-9, thus inhibiting programmed cell death. It has been shown that in the cell this interaction can be displaced by the protein second mitochondrial activator of caspases (SMAC) and that its N-terminal tetrapeptide region (NH2-AVPI, Ala-Val-Pro-Ile) is responsible for this activity. However, because of their limited cell permeability, synthetic SMAC peptides are inefficient when tested in cultured cells, limiting their use as potential chemical tools or drug candidates against cancer cells. Hence, as an application, we report on the derivation of novel, selective, druglike, cell permeable SMAC mimics with cellular activity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18956862      PMCID: PMC2692895          DOI: 10.1021/jm8006992

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  40 in total

1.  Structural biology. Controlling the caspases.

Authors:  S W Fesik; Y Shi
Journal:  Science       Date:  2001-11-16       Impact factor: 47.728

2.  Non-peptidic small molecule inhibitors of XIAP.

Authors:  Cheol-Min Park; Chaohong Sun; Edward T Olejniczak; Alan E Wilson; Robert P Meadows; Stephen F Betz; Steven W Elmore; Stephen W Fesik
Journal:  Bioorg Med Chem Lett       Date:  2005-02-01       Impact factor: 2.823

3.  Design, synthesis, and characterization of a potent, nonpeptide, cell-permeable, bivalent Smac mimetic that concurrently targets both the BIR2 and BIR3 domains in XIAP.

Authors:  Haiying Sun; Zaneta Nikolovska-Coleska; Jianfeng Lu; Jennifer L Meagher; Chao-Yie Yang; Su Qiu; York Tomita; Yumi Ueda; Sheng Jiang; Krzysztof Krajewski; Peter P Roller; Jeanne A Stuckey; Shaomeng Wang
Journal:  J Am Chem Soc       Date:  2007-11-14       Impact factor: 15.419

4.  A small molecule Smac-mimic compound induces apoptosis and sensitizes TRAIL- and etoposide-induced apoptosis in breast cancer cells.

Authors:  Katrina M Bockbrader; Mingjia Tan; Yi Sun
Journal:  Oncogene       Date:  2005-11-10       Impact factor: 9.867

5.  Molecular recognition of receptor sites using a genetic algorithm with a description of desolvation.

Authors:  G Jones; P Willett; R C Glen
Journal:  J Mol Biol       Date:  1995-01-06       Impact factor: 5.469

6.  Structural basis of IAP recognition by Smac/DIABLO.

Authors:  G Wu; J Chai; T L Suber; J W Wu; C Du; X Wang; Y Shi
Journal:  Nature       Date:  2000 Dec 21-28       Impact factor: 49.962

7.  A single BIR domain of XIAP sufficient for inhibiting caspases.

Authors:  R Takahashi; Q Deveraux; I Tamm; K Welsh; N Assa-Munt; G S Salvesen; J C Reed
Journal:  J Biol Chem       Date:  1998-04-03       Impact factor: 5.157

8.  Bioluminescence of cellular ATP: a new method for evaluating cytotoxic agents in vitro.

Authors:  L Kangas; M Grönroos; A L Nieminen
Journal:  Med Biol       Date:  1984

9.  Triptolide sensitizes AML cells to TRAIL-induced apoptosis via decrease of XIAP and p53-mediated increase of DR5.

Authors:  Bing Z Carter; Duncan H Mak; Wendy D Schober; Martin F Dietrich; Clemencia Pinilla; Lyubomir T Vassilev; John C Reed; Michael Andreeff
Journal:  Blood       Date:  2008-01-10       Impact factor: 22.113

10.  Structure-based design, synthesis, and evaluation of conformationally constrained mimetics of the second mitochondria-derived activator of caspase that target the X-linked inhibitor of apoptosis protein/caspase-9 interaction site.

Authors:  Haiying Sun; Zaneta Nikolovska-Coleska; Chao-Yie Yang; Liang Xu; York Tomita; Krzysztof Krajewski; Peter P Roller; Shaomeng Wang
Journal:  J Med Chem       Date:  2004-08-12       Impact factor: 7.446

View more
  14 in total

1.  Computational fragment-based screening using RosettaLigand: the SAMPL3 challenge.

Authors:  Ashutosh Kumar; Kam Y J Zhang
Journal:  J Comput Aided Mol Des       Date:  2012-01-15       Impact factor: 3.686

2.  Emerging Therapeutic Targets in Diffuse Large B-Cell Lymphoma.

Authors:  Murali Janakiram; Venu K Thirukonda; Matthew Sullivan; Adam M Petrich
Journal:  Curr Treat Options Oncol       Date:  2012-02-02

Review 3.  From laptop to benchtop to bedside: structure-based drug design on protein targets.

Authors:  Lu Chen; John K Morrow; Hoang T Tran; Sharangdhar S Phatak; Lei Du-Cuny; Shuxing Zhang
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

4.  Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity.

Authors:  Wyndham H Wilson; Owen A O'Connor; Myron S Czuczman; Ann S LaCasce; John F Gerecitano; John P Leonard; Anil Tulpule; Kieron Dunleavy; Hao Xiong; Yi-Lin Chiu; Yue Cui; Todd Busman; Steven W Elmore; Saul H Rosenberg; Andrew P Krivoshik; Sari H Enschede; Rod A Humerickhouse
Journal:  Lancet Oncol       Date:  2010-11-18       Impact factor: 41.316

Review 5.  The rise of fragment-based drug discovery.

Authors:  Christopher W Murray; David C Rees
Journal:  Nat Chem       Date:  2009-06       Impact factor: 24.427

Review 6.  Small molecules, big targets: drug discovery faces the protein-protein interaction challenge.

Authors:  Duncan E Scott; Andrew R Bayly; Chris Abell; John Skidmore
Journal:  Nat Rev Drug Discov       Date:  2016-04-11       Impact factor: 84.694

Review 7.  Targeting protein-protein interactions in hematologic malignancies: still a challenge or a great opportunity for future therapies?

Authors:  Tomasz Cierpicki; Jolanta Grembecka
Journal:  Immunol Rev       Date:  2015-01       Impact factor: 12.988

8.  The Cell Surface Receptor CD44: NMR-Based Characterization of Putative Ligands.

Authors:  Carlo Baggio; Elisa Barile; Gianluigi Di Sorbo; Thomas J Kipps; Maurizio Pellecchia
Journal:  ChemMedChem       Date:  2016-05-04       Impact factor: 3.466

Review 9.  PubChem applications in drug discovery: a bibliometric analysis.

Authors:  Tiejun Cheng; Yongmei Pan; Ming Hao; Yanli Wang; Stephen H Bryant
Journal:  Drug Discov Today       Date:  2014-08-27       Impact factor: 7.851

10.  Engineering a leucine zipper-TRAIL homotrimer with improved cytotoxicity in tumor cells.

Authors:  Dmitri V Rozanov; Alexei Y Savinov; Vladislav S Golubkov; Olga L Rozanova; Tatiana I Postnova; Eduard A Sergienko; Stefan Vasile; Alexander E Aleshin; Michele F Rega; Maurizio Pellecchia; Alex Y Strongin
Journal:  Mol Cancer Ther       Date:  2009-06-09       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.